Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

F-Star Biotechnology Ltd.. (1/9/18). "Press Release: F-Star Provides an Update on Its Collaboration with Denali Therapeutics". Cambridge.

Organisations Organisation F-Star Biotechnology Ltd. (F-Star Therapeutics)
  Group Sino Biopharm (Group)
  Organisation 2 Denali Therapeutics Inc. (Nasdaq: DNLI)
  Group Denali Therapeutics (Group)
Products Product Antibody Transport Vehicle technology (ATV technology)
  Product 2 Fcab® antibody fragment
  Index term 2 Takeda–Denali Therapeutics: neurological drugs, 201801– collab + option agreem for 3 drug candidates for neurodegenerative diseases
Persons Person Haurum, John (F-Star 201205–201810 CEO before ImClone System + Symphogen LEFT 10/18)
  Person 2 Peotta, Pierre (F-Star 201801 Communications Manager)

F-star, a biopharmaceutical company developing novel bispecific antibodies, today provides an update on its collaboration with Denali Therapeutics (NASDAQ: DNLI).

Denali Therapeutics and Takeda Pharmaceutical Company Limited (TSE: 4502) on Friday 5 January 2018 announced that they had entered into a strategic option and collaboration agreement to develop and commercialise up to three specified therapeutic product candidates for neurodegenerative diseases.

These three therapeutic programmes are based on Denali's ATV (Antibody Transport Vehicle) technology and include transferrin receptor-specific Fcabs™ (Fc-domains with antigen-binding activity) that were discovered under the collaboration with F-star, announced in August 2016. This collaboration leverages F-star’s Modular Antibody TechnologyTM and Denali’s expertise in the development of therapeutics for neurological diseases. The collaboration is held within F-star Gamma Limited (F-star Gamma), an AssetCentric Vehicle in the F-star family.

John Haurum, CEO of F-star commented “Denali Therapeutics’ agreement with Takeda is extremely exciting news for F-star and provides clear validation of our technology. It underlines the positive progress in our collaboration.”

Under the terms of the agreement F-star announced with Denali in 2016, F-star has already received upfront payments totaling $6M, as well as research funding and is eligible for technical milestone payments. In addition, Denali has the option to acquire F-star Gamma prior to the initiation of the first Phase 1 clinical trial in return for aggregate exercise and milestone payments to the F-star Gamma shareholders of up to $450M in total. If Denali does not exercise the option to acquire F-star Gamma, it has the right to license a pre-specified number of mAb² based on each Fcab generated by F-star Gamma, in return for license fees, development, regulatory and commercial milestones payments with a potential aggregate value of $1B and tiered royalties on product sales.


For further information, please contact:

At F-star
Pierre Peotta
Communications Manager
+44 (0)7392 080 279

Media enquiries

Instinctif Partners (EU & RoW)
Sue Charles/Ashley Tapp
+44 (0)20 7866 7923

Lazar Partners (USA)
Glenn Silver
+1 (0)212 867 1762

About F-star

F-star is a clinically-validated biopharmaceutical company developing immuno-oncology bispecific antibody therapeutics selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to rapidly create bispecific antibodies with properties virtually identical to a typical antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star entered one programme in the clinic and a second immuno-oncology programme is heading toward IND. The company has built a comprehensive IP estate around its technology and product pipeline.

F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Merck and Denali Therapeutics. F-star has raised close to $200M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.

For more information visit

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Sino Biopharm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top